ORPHA:2133
Hemoglobin E disease
Publications
163
51.9th percentile
Trials
0
Interventional, condition-specific
Researchers
775
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Hemoglobin E disease (HbE) is a hemoglobinopathy characterized by production of abnormal variant hemoglobin known as hemoglobin E, with a generally benign, asymptomatic presentation.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016243
- UMLS:C0238159
- NCIT:C35287
Additional Mondo synonyms (1)
hemoglobin E disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
163 matched papers (68 in last 10 years) Source
- Phenotype characterisedPresent
12 HPO annotations (e.g. Hypochromic microcytic anemia; Premature birth; Splenomegaly) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
12
Associated phenotypes · MONDO:0016243
- Hypochromic microcytic anemia
- Premature birth
- Splenomegaly
- Hypochromia
- Reduced hemoglobin A
Showing 5 of 12 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
163
163 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
163 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
68 in the last 10 years · high confidence · 51.9th percentile (publications denominator)
Phrase hits: 163 · MeSH hits: 0
Who's working on it?
775
Distinct author names in 163 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Fucharoen S14 papers · 2022
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.
Papers in Europe PMC - 02Estcourt LJ8 papers · 2023
Haematology/Transfusion Medicine, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, UK, OX3 9BQ.
Papers in Europe PMC - 03Wasi P8 papers · 2000Papers in Europe PMC
- 04Hopewell S7 papers · 2020
Oxford Clinical Trials Research Unit, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Windmill Road, Oxford, Oxfordshire, UK, OX3 7LD.
Papers in Europe PMC - 05Tongsong T7 papers · 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand.
Papers in Europe PMC - 06Trivella M7 papers · 2020
Centre for Statistics in Medicine, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, UK, OX3 7LD.
Papers in Europe PMC - 07Doree C5 papers · 2020
Systematic Review Initiative, NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK, OX3 9BQ.
Papers in Europe PMC - 08Fortin PM5 papers · 2017
Systematic Review Initiative, NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK, OX3 9BQ.
Papers in Europe PMC - 09Pootrakul P5 papers · 2004
Thalassaemia Research Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Nakornpathom, Thailand.
Papers in Europe PMC - 10Winichagoon P5 papers · 1996
Thalassemia Center, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 39 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 39 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (39)
- isrctn·ISRCTN34498249·Recruiting·A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (BOS-580-302)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11301892·No longer recruiting·Biological impact of an intensive 21-day spa recovery program on quality of life and cell health in Parkinson’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49366748·No longer recruiting·A phase II study to test the safety and effects of BC-006 Injection in adults with obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80147609·Recruiting·A study comparing JNJ-79635322 and an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody in participants with relapsed or refractory multiple myeloma (Trilogy-4)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97110708·Recruiting·How the body processes doses of hormone and NSAID drugs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72565988·No longer recruiting·Effects of plant-based probiotic supplementation on health
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59381053·No longer recruiting·Testing whether taking aspirin before surgery can help prevent blood clots in people having orthopaedic operations
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14210300·Recruiting·A study of a natural fruit (plum) extract and choline on liver health and metabolism in adults with fatty liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18233037·No longer recruiting·Tai Chi in type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10195062·No longer recruiting·Evaluation of the efficacy of a food supplement for subjects with metabolic syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19477801·No longer recruiting·Evaluation of the efficacy of a food supplement in improving sports performance, recovery and joint wellbeing
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14004195·No longer recruiting·Evaluation of the efficacy of a food supplement on hair trophism and normal growth in subjects with androgenetic alopecia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83576037·No longer recruiting·A phase 2, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy study of a subcutaneous injection of BC-006 and tirzepatide in adults with obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12954826·No longer recruiting·How gum treatment may help improve blood sugar control in people with type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11357259·Recruiting·An early safety study testing a drug combination given before possible surgery for people with pancreatic cancer that can’t be easily removed yet or hasn’t spread far
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18283468·No longer recruiting·A clinical trial to learn more about the absorption of radiolabeled drug LXE408, how the body breaks it down, and how quickly the body gets rid of it in healthy men
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10259827·No longer recruiting·Effects of twelve weeks of telecare-based elastic band resistance exercise training after laparoscopic sleeve gastrectomy in physical fitness, body composition and nutritional intake
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN94981477·Recruiting·Tranexamic acid for anaemia trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11365927·Recruiting·Towards a more green and healthy food culture - Organic food, sustainability and health on one plate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81317148·No longer recruiting·Clinical study to assess the efficacy of a food supplement for hair care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66268301·No longer recruiting·Effects of guanidinoacetic acid and creatine monohydrate supplementation on markers of health and cognitive function
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57160973·Recruiting·A lifestyle intervention to reduce cardiometabolic risk factors in individuals with obsessive-compulsive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22102770·Recruiting·A study to test the safety and effects of a New Drug (LAE103) in healthy people who are overweight or obese, and in healthy postmenopausal women. The study also looks at how LAE103 works when taken alone or together with another drug (LAE102).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23559139·Recruiting·Effects of probiotic supplementation on ratings of menopause and markers of health in women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13410885·No longer recruiting·The beneficial effect of two varieties of apples, such as Golden Delicious and Canadian White Renetta, on the improvement of normal lipid and glucose metabolism in insulin-resistant subjects with and without a diagnosis of non-alcoholic fatty liver disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hemoglobin E disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hemoglobin E disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hemoglobin E disease"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T19:13:32.049Z
